TTP plc

Nr Royston,  Hertfordshire 
United Kingdom
http://www.ttp.com/desktopbiology
  • Booth: 1472

Booth Profile

Your biology. Enabled. TTP’s Desktop Biology brings a truly multidisciplinary approach to diagnostic system development. Our team of over 200 engineers, chemists, biologists and physicists stands ready to develop products and instruments based on your assays and technologies. Where suitable, developments are enabled by our existing platforms and IP for providing a fast track route to product. www.ttp.com/desktopbiology


 Press Releases

  • Cambridge, UK, 09 May 2018: TTP Plc (TTP), a leading independent technology and product development company, and Camena Bioscience, a developer of pioneering technology that profiles small molecules, such as metabolites, nutrients or medicines in liquid samples, announced today that they are collaborating to develop an instrument to monitor the health of cell cultures. The new instrument will be used in biologic medicine manufacturing, and will be developed by TTP as part of a new project led by Camena Bioscience and co-funded by Innovate UK, the UK’s innovation agency, with GSK plc and The Centre for Process Innovation as further project partners.

    TTP will integrate Camena Bioscience’s proprietary small-molecule detection technology into a new instrument that will allow researchers to monitor metabolite levels in cell cultures more easily. The resulting better understanding of the condition of the cell culture, which is crucial for consistent synthesis of high-quality biologic products, promises to substantially improve the efficiency and cost of biologic medicine manufacturing.

    Camena Bioscience won the Innovate UK funding for the consortium to commercialise a proprietary small-molecule detection technology, and TTP was chosen to lead on the design and development of an analytical reader and housing for the biosensors. Leveraging TTP’s 30-year track record in life science instrument development, the partnership aims to deliver a desktop analytical instrument that is versatile, yet easy to use and compact, to create a powerful new tool for bioprocess development labs globally.

    Jana Voigt, COO of Camena Bioscience, explained the potential applications: "Existing technologies only permit the monitoring of a few types of small molecules in cell culture, or typically require large, complex and expensive lab equipment. Camena Bioscience’s sensor technology will extend the range of small molecules that can be monitored in cell culture, allow for simultaneous detection of multiple metabolites, and ensure that the new instrument provides rapid and accurate results from small samples of the culture medium."

    Stuart Lowe, Life Science Consultant at TTP, commented on the announcement: "In recent years the Life Science Group at TTP has been driving innovation in the bioprocessing market. Camena Bioscience has an exciting and timely new technology – their instrument vision is complementary to much of the work that TTP has been undertaking in Desktop Biology, with the goal of democratizing analysis through increased simplicity and smaller system footprint. We look forward to working with the consortium Camena Bioscience has built to capitalise on their sensor technology."

    ENDS

    Media contact:

    Zyme Communications

    Lorna Cuddon

    Tel: +44 (0)7811 996 942

    Email: lorna.cuddon@zymecommunications.com

    About TTP plc www.ttp.com

    TTP’s core business is in new technology and product development, specialising in fast track engineering, from design to manufacture. Founded in 1987, TTP Group employs over 400 engineering and technical staff at their Cambridge, UK campus.

    About Camena Bioscience www.camenabio.com

    Camena Bioscience is the developer of pioneering technology that profiles small molecules, such as metabolites, nutrients or medicines in liquid samples. The company’s aim is to enable a new generation of small molecule analysis that improves the understanding of biological processes and how they can be manipulated for biological manufacturing. Camena Bioscience is based in Cambridge, UK and Pasadena, USA.

    • NESDEP portable laboratory for pathogen detection is now being transferred for manufacture
    • NESDEP detects pathogens in less than 90 minutes, and aims to provide significant cost savings whilst reducing the incidence of foodborne illnesses

    Cambridge, UK, 02 July 2018: TTP plc (TTP), a leading independent technology and product development company, and Cubed Laboratories (Cubed), a developer of rapid, DNA-based molecular diagnostic devices and test kits, today announced the successful completion of a project to develop Cubed’s core product, the NESDEP portable laboratory for pathogen detection. This accurate, high-throughput, and easy-to-use system has benefits in the food safety industry and potentially beyond. 

    Cubed engaged TTP towards the end of 2017 to undertake a rapid redesign and repackaging of its NESDEP device. Working from the base technology developed by Cubed, TTP’s Desktop Biology team conducted a bottom-up repackaging and development programme focussing on aesthetics, ease-of-use, and manufacturability. In May 2018, TTP hosted Bruce Brock, CEO of Cubed and Gabe Shakour, their Director of Manufacturing. This workshop marked the beginning of formally transferring the design to manufacture. TTP has now shipped pre-production prototypes to Cubed, and manufacture of the system is underway.

    The newest market-ready NESDEP permits the detection of pathogens in less than 90 minutes, from introduction of a raw sample to the full completion of the assay. NESDEP is a portable laboratory that can be used by a lay person without specialised training or experience. It can be used in virtually any indoor or outdoor location with access to power. Each NESDEP test kit contains a biochip programmed to test for specific biological material, and aims to improve quality management processes in the food and beverage industries. NESDEP will provide customers with significant cost savings and aid in the effort to reduce the incidence of foodborne illnesses.

    Les Ivie, COO of Cubed, said: "TTP and Cubed have a long-standing relationship. Previously TTP partnered with us in helping commercialise our breakthrough technology. Now we have successfully partnered again, two leaders in their respective fields, Cubed for it breakthrough technology and TTP for its product engineering expertise, to deliver this revolutionary rapid diagnostic device.

    We are looking forward to future partnerships with TTP as we seek to further expand our product portfolio."

    Stuart Lowe, Life Science Consultant at TTP, commented: "Cubed was one of the earliest beneficiaries of TTP’s Desktop Biology initiative, providing development expertise for those looking to enable analytical-quality testing at the point-of-decision, rather than relying on central laboratory services. We are delighted to have partnered with Cubed in the commercialising of the NESDEP device."

    ENDS

    Notes to Editors

    For high-resolution images please contact lorna.cuddon@zymecommunications.com

    Image: NESDEP portable laboratory for pathogen detection

    Media contact:

    Zyme Communications

    Lorna Cuddon

    Tel: +44 (0)7811 996 942

    Email: lorna.cuddon@zymecommunications.com 


    About TTP plc www.ttp.com  

    TTP’s core business is in new technology and product development, specialising in fast track engineering, from design to manufacture. Founded in 1987, TTP Group employs over 400 engineering and technical staff at their Cambridge, UK campus.

    About Cubed Laboratories www.cubedlabs.com  

    Cubed Laboratories develops ground breaking, patented technologies which are changing the face of diagnostic testing in the food industry, environmental testing and medical diagnostics. Cubed Lab's core product, NESDEP, is a rapid DNA based molecular detector that enables companies to significantly reduce both their costs and the incidence of foodborne illness.

  • A novel and disruptive analysis and monoclonal assurance system for drug discovery and development

    Cambridge, UK, 17 October 2017: TTP Plc (TTP), a leading independent technology and product development company, and Sphere Fluidics, which provides single cell analysis systems underpinned by its patented picodroplet technology, today announced the launch of the Cyto-Mine® Single Cell Analysis System. The Cyto-Mine system automates single cell analysis, sorting, imaging and dispensing to help boost throughput and sensitivity throughout the biopharmaceutical discovery process.

    Sphere Fluidics approached TTP to address the challenges associated with the development of a highly complex laboratory instrument and microfluidic cartridge. In less than three years, the partnership has delivered the Cyto-Mine instrument, based on proprietary algorithm software and optical hardware from Sphere Fluidics, which enables single cell compartmentalisation and fluorescence-assisted sorting. The instrument is compatible with the Cyto-Cartridge®, a disposable microfluidic biochip that integrates Sphere Fluidics’ core technology in picodroplet generation and sorting for cellular applications with TTP’s dispensing technology. The Cyto-Cartridge allows single cells of interest to be dispensed into individual wells of a microtitre plate for biopharma discovery, cell line development and monoclonality assurance. This enables a step change in throughput for biopharma applications.

    The Cyto-Mine is the first integrated device to automatically perform all of the techniques routinely used in the biopharmaceutical discovery and development workflow, in a single compact GLP-compliant system that fits in a standard biological safety cabinet. Traditionally, up to three different items of equipment would be required for each step, resulting in a costly and time-consuming process, using up valuable lab space and increasing the risk of sample contamination. The Cyto-Mine system can deliver up to 10 million tests in a single day compared to other systems on the market that deliver 10,000 tests in three weeks. The high-throughput instrument uses Sphere Fluidics’ patented picodroplet technology to encapsulate a single cell in growth media and trap secreted molecules, such as antibodies, from the cell as it grows. Since each cell is compartmentalised in the disposable Cyto-Cartridge, monoclonality is assured and the unique workflow enables selective screening of single cells to find rare lead candidates. 

    Dr Frank Craig, CEO and Director at Sphere Fluidics commented: “TTP has a world-class reputation for excellence in developing highly complex instrumentation effectively. Their multi-disciplinary team are highly experienced and were able to deliver in a variety of areas from optics to fluidics, from software to systems integration very quickly. This, coupled with their commercial acumen and drive to bring our idea to reality, made them the ideal partner.”

    For more information on the Cyto-Mine, please visit: http://www.spherefluidics.com/products/integrated-systems/cyto-mine/

    ENDS


    Notes to Editor

    For a high-resolution image please contact Zyme Communications.

    For further information please contact:

    Zyme Communications

    Lorna Cuddon

    Tel: +44 (0)7811 996 942

    Email: lorna.cuddon@zymecommunications.com

     

    About TTP Plc www.ttp.com

    TTP plc is Europe’s leading independent technology and product development company. Part of TTP Group, it combines the strengths of science, engineering and business enterprise to develop new technologies, new products, and new businesses. TTP Group is headquartered on Melbourn Science Park (near Cambridge, UK) and currently employs over 400 people in its businesses, of whom the majority are scientists and engineers.

     

    About Sphere Fluidics www.spherefluidics.com

    Sphere Fluidics Limited is an established Life Sciences Tools company commercialising single cell analysis systems for therapeutic discovery. Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA) and has 22 employees, the majority of whom are PhD scientists and engineers. The company is also internationalising its business via a global network of distributors.

     

    Cyto-Mine and Cyto-Cartridge are registered trademarks.